{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T02:25:35Z","timestamp":1780626335461,"version":"3.54.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,3,13]],"date-time":"2023-03-13T00:00:00Z","timestamp":1678665600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,3,13]],"date-time":"2023-03-13T00:00:00Z","timestamp":1678665600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1007\/s00520-023-07676-9","type":"journal-article","created":{"date-parts":[[2023,3,26]],"date-time":"2023-03-26T22:14:51Z","timestamp":1679868891000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Identifying risk factors for opioid-induced neurotoxicity in cancer patients receiving oxycodone"],"prefix":"10.1007","volume":"31","author":[{"given":"Takashi","family":"Omoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junichi","family":"Asaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoru","family":"Nihei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenzo","family":"Kudo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,13]]},"reference":[{"key":"7676_CR1","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1093\/annonc\/mdm056","volume":"18","author":"MH Van den Beuken-van Everdingen","year":"2007","unstructured":"Van den Beuken-van Everdingen MH, De Rijke JM, Kessels AG, Schouten HC, Van Kleef M, Patijn J (2007) Prevalence of pain in patients with cancer: a systematic review of the past 40 years. Ann Oncol 18:1437\u20131449. https:\/\/doi.org\/10.1093\/annonc\/mdm056","journal-title":"Ann Oncol"},{"key":"7676_CR2","doi-asserted-by":"publisher","first-page":"515","DOI":"10.2147\/JPR.S97759","volume":"9","author":"CL Carlson","year":"2016","unstructured":"Carlson CL (2016) Effectiveness of the World Health Organization cancer pain relief guidelines: an integrative review. J Pain Res 9:515\u2013534. https:\/\/doi.org\/10.2147\/JPR.S97759","journal-title":"J Pain Res"},{"key":"7676_CR3","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1136\/bmjspcare-2017-001457","volume":"8","author":"M Schmidt-Hansen","year":"2018","unstructured":"Schmidt-Hansen M, Bennett MI, Arnold S, Bromham N, Hilgart JS (2018) Efficacy, tolerability and acceptability of oxycodone for cancer-related pain in adults: an updated Cochrane systematic review. BMJ Support Palliat Care 8:117\u2013128. https:\/\/doi.org\/10.1136\/bmjspcare-2017-001457","journal-title":"BMJ Support Palliat Care"},{"key":"7676_CR4","doi-asserted-by":"publisher","first-page":"e0231763","DOI":"10.1371\/journal.pone.0231763","volume":"15","author":"J Zhou","year":"2020","unstructured":"Zhou J, Wang Y, Jiang G (2020) Oxycodone versus morphine for cancer pain titration: a systematic review and pharmacoeconomic evaluation. PLoS One 15:e0231763. https:\/\/doi.org\/10.1371\/journal.pone.0231763","journal-title":"PLoS One"},{"key":"7676_CR5","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1007\/s00520-014-2132-4","volume":"22","author":"M Nagashima","year":"2014","unstructured":"Nagashima M, Ooshiro M, Moriyama A, Sugishita Y, Kadoya K, Sato A, Kitahara T, Takagi R, Urita T, Yoshida Y, Tanaka H, Oshiro T, Okazumi S, Katoh R (2014) Efficacy and tolerability of controlled-release oxycodone for oxaliplatin-induced peripheral neuropathy and the extension of FOLFOX therapy in advanced colorectal cancer patients. Support Care Cancer 22:1579\u20131584. https:\/\/doi.org\/10.1007\/s00520-014-2132-4","journal-title":"Support Care Cancer"},{"key":"7676_CR6","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/s1526-5900(03)00556-x","volume":"4","author":"E McNicol","year":"2003","unstructured":"McNicol E, Horowicz-Mehler N, Fisk RA, Bennett K, Gialeli-Goudas M, Chew PW, Lau J, Carr D, Americal Pain Society (2003) Management of opioid side effects in cancer-related and chronic noncancer pain: a systematic review. J Pain 4:231\u2013256. https:\/\/doi.org\/10.1016\/s1526-5900(03)00556-x","journal-title":"J Pain"},{"key":"7676_CR7","doi-asserted-by":"publisher","first-page":"iv166","DOI":"10.1093\/annonc\/mdy152","volume":"29","author":"M Fallon","year":"2018","unstructured":"Fallon M, Giusti R, Aielli F, Hoskin P, Rolke R, Sharma M, Ripamonti CI, ESMO Guidelines Committee (2018) Management of cancer pain in adult patients: ESMO Clinical Practice Guidelines. Ann Oncol 29:iv166\u2013iv191. https:\/\/doi.org\/10.1093\/annonc\/mdy152","journal-title":"Ann Oncol"},{"key":"7676_CR8","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1089\/jpm.2018.0169","volume":"21","author":"KH Lim","year":"2018","unstructured":"Lim KH, Nguyen NN, Qian Y, William JL, Lui DD, Bruera E, Yennurajalingam S (2018) Frequency, outcomes, and associated factors for opioid-induced neurotoxicity in patients with advanced cancer receiving opioids in inpatient palliative care. J Palliat Med 21:1698\u20131704. https:\/\/doi.org\/10.1089\/jpm.2018.0169","journal-title":"J Palliat Med"},{"key":"7676_CR9","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1634\/theoncologist.2012-0269","volume":"18","author":"A Reddy","year":"2013","unstructured":"Reddy A, Yennurajalingam S, Pulivarthi K, Palla SL, Wang X, Kwon JH, Frisbee-Hume S, Bruera E (2013) Frequency, outcome, and predictors of success within 6 weeks of an opioid rotation among outpatients with cancer receiving strong opioids. Oncologist 18:212\u2013220. https:\/\/doi.org\/10.1634\/theoncologist.2012-0269","journal-title":"Oncologist"},{"key":"7676_CR10","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1007\/s00520-018-4367-y","volume":"27","author":"H Hamano","year":"2019","unstructured":"Hamano H, Mitsui M, Zamami Y, Takechi K, Nimura T, Okada N, Fukushima K, Imanishi M, Chuma M, Horinouchi Y, Izawa-Ishizawa Y, Kirino Y, Nakamura T, Teraoka K, Ikeda Y, Fujino H, Yanagawa H, Tamaki T, Ishizawa K (2019) Irinotecan-induced neutropenia is reduced by oral alkalization drugs: analysis using retrospective chart reviews and the spontaneous reporting database. Support Care Cancer 27:849\u2013856. https:\/\/doi.org\/10.1007\/s00520-018-4367-y","journal-title":"Support Care Cancer"},{"key":"7676_CR11","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1248\/bpb.b19-00105","volume":"42","author":"H Sugawara","year":"2019","unstructured":"Sugawara H, Uchida M, Suzuki S, Suga Y, Uesawa Y, Nakagawa T, Takase H (2019) Analyses of respiratory depression associated with opioids in cancer patients based on the Japanese Adverse Drug Event Report database. Biol Pharm Bull 42:1185\u20131191. https:\/\/doi.org\/10.1248\/bpb.b19-00105","journal-title":"Biol Pharm Bull"},{"key":"7676_CR12","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1248\/bpb.b20-00904","volume":"44","author":"T Omoto","year":"2021","unstructured":"Omoto T, Asaka J, Sakai T, Sato F, Goto N, Kudo K (2021) Disproportionality analysis of safety signals for a wide variety of opioid-related adverse events in elderly patients using the Japanese Adverse Drug Event Report (JADER) Database. Biol Pharm Bull 44:627\u2013634. https:\/\/doi.org\/10.1248\/bpb.b20-00904","journal-title":"Biol Pharm Bull"},{"key":"7676_CR13","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1159\/000180580","volume":"16","author":"DW Cockcroft","year":"1976","unstructured":"Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31\u201341. https:\/\/doi.org\/10.1159\/000180580","journal-title":"Nephron"},{"key":"7676_CR14","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y (2013) Investigation of the freely available easy-to-use software \u201cEZR\u201d for medical statistics. Bone Marrow Transplant 48:452\u2013458. https:\/\/doi.org\/10.1038\/bmt.2012.244","journal-title":"Bone Marrow Transplant"},{"key":"7676_CR15","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1093\/jjco\/hyac122","volume":"52","author":"R Takahashi","year":"2022","unstructured":"Takahashi R, Miyashita M, Murakami Y, Oba MS (2022) Trends in strong opioid prescription for cancer patients in Japan from 2010 to 2019: an analysis with large medical claims data. Jpn J Clin Oncol 52:1297\u20131302. https:\/\/doi.org\/10.1093\/jjco\/hyac122","journal-title":"Jpn J Clin Oncol"},{"key":"7676_CR16","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.jpainsymman.2012.03.011","volume":"45","author":"AM Gilson","year":"2013","unstructured":"Gilson AM, Maurer MA, Ryan KM, Rathouz PJ, Cleary JF (2013) Using a morphine equivalence metric to quantify opioid consumption: examining the capacity to provide effective treatment of debilitating pain at the global, regional, and country levels. J Pain Symptom Manage 45:681\u2013700. https:\/\/doi.org\/10.1016\/j.jpainsymman.2012.03.011","journal-title":"J Pain Symptom Manage"},{"key":"7676_CR17","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1093\/annonc\/mdw097","volume":"27","author":"O Corli","year":"2016","unstructured":"Corli O, Floriani I, Roberto A, Montanari M, Galli F, Greco MT, Caraceni A, Kaasa S, Dragani TA, Azzarello G, Luzzani M, Cavanna L, Bandieri E, Gamucci T, Lipari G, Di Gregorio R, Valenti D, Reale C, Pavesi L, Iorno V, Crispino C, Pacchioni M, Apolone G, CERP STUDY OF PAIN GROUP (List of collaborators) (2016) Are strong opioids equally effective and safe in the treatment of chronic cancer pain? A multicenter randomized phase IV \u2018real life\u2019 trial on the variability of response to opioids. Ann Oncol 27:1107\u20131115. https:\/\/doi.org\/10.1093\/annonc\/mdw097","journal-title":"Ann Oncol"},{"key":"7676_CR18","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1111\/pme.12865","volume":"17","author":"J Winegarden","year":"2016","unstructured":"Winegarden J, Carr DB, Bradshaw YS (2016) Intravenous ketamine for rapid opioid dose reduction, reversal of opioid-induced neurotoxicity, and pain control in terminal care: case report and literature review. Pain Med 17:644\u2013649. https:\/\/doi.org\/10.1111\/pme.12865","journal-title":"Pain Med"},{"key":"7676_CR19","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1177\/2042098615615472","volume":"7","author":"AH Lavan","year":"2016","unstructured":"Lavan AH, Gallagher P (2016) Predicting risk of adverse drug reactions in older adults. Ther Adv Drug Saf 7:11\u201322. https:\/\/doi.org\/10.1177\/2042098615615472","journal-title":"Ther Adv Drug Saf"},{"key":"7676_CR20","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1007\/s00520-002-0385-9","volume":"11","author":"MP Davis","year":"2003","unstructured":"Davis MP, Varga J, Dickerson D, Walsh D, LeGrand SB, Lagman R (2003) Normal-release and controlled-release oxycodone: pharmacokinetics, pharmacodynamics, and controversy. Support Care Cancer 11:84\u201392. https:\/\/doi.org\/10.1007\/s00520-002-0385-9","journal-title":"Support Care Cancer"},{"key":"7676_CR21","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/0952-8180(95)00092-5","volume":"8","author":"M Kirvela","year":"1996","unstructured":"Kirvela M, Lindgren L, Seppala T, Olkkola K (1996) The pharmacokinetics of oxycodone in uremic patients undergoing renal transplantation. J Clin Anesth 8:13\u201318. https:\/\/doi.org\/10.1016\/0952-8180(95)00092-5","journal-title":"J Clin Anesth"},{"key":"7676_CR22","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/S0009-9236(97)90100-4","volume":"61","author":"M Tallgren","year":"1997","unstructured":"Tallgren M, Olkkola KT, Seppala T, Hockerstedt K, Lindgren L (1997) Pharmacokinetics and ventilatory effects of oxycodone before and after liver transplantation. Clin Pharmacol Ther 61:655\u2013661. https:\/\/doi.org\/10.1016\/S0009-9236(97)90100-4","journal-title":"Clin Pharmacol Ther"},{"key":"7676_CR23","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1093\/bja\/aer395","volume":"108","author":"TI Saari","year":"2012","unstructured":"Saari TI, Ihmsen H, Neuvonen PJ, Olkkola KT, Schwilden H (2012) Oxycodone clearance is markedly reduced with advancing age: a population pharmacokinetic study. Br J Anaesth 108:491\u2013498. https:\/\/doi.org\/10.1093\/bja\/aer395","journal-title":"Br J Anaesth"},{"key":"7676_CR24","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1007\/s00228-010-0948-5","volume":"67","author":"TN Andreassen","year":"2011","unstructured":"Andreassen TN, Klepstad P, Davies A, Bjordal K, Lundstr\u00f6m S, Kaasa S, Dale O (2011) Influences on the pharmacokinetics of oxycodone: a multicentre cross-sectional study in 439 adult cancer patients. Eur J Clin Pharmacol 67:493\u2013506. https:\/\/doi.org\/10.1007\/s00228-010-0948-5","journal-title":"Eur J Clin Pharmacol"},{"key":"7676_CR25","unstructured":"Oxycodone hydrochloride hydrate drug package insert: https:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuDetail\/ResultDataSetPDF\/343018_8119002G5020_2_04. Accessed 22 Feb 2022"},{"key":"7676_CR26","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s00520-013-1973-6","volume":"22","author":"B Charles","year":"2014","unstructured":"Charles B, Hardy J, Anderson H, Tapuni A, George R, Norris R (2014) Should the dosage of controlled-release oxycodone in advanced cancer be modified on the basis of patient characteristics? Support Care Cancer 22:325\u2013330. https:\/\/doi.org\/10.1007\/s00520-013-1973-6","journal-title":"Support Care Cancer"},{"key":"7676_CR27","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1007\/s00520-016-3447-0","volume":"25","author":"TA Sande","year":"2017","unstructured":"Sande TA, Laird BJ, Fallon MT (2017) The use of opioids in cancer patients with renal impairment-a systematic review. Support Care Cancer 25:661\u2013675. https:\/\/doi.org\/10.1007\/s00520-016-3447-0","journal-title":"Support Care Cancer"},{"key":"7676_CR28","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1007\/s00520-021-06585-z","volume":"30","author":"S Yokoyama","year":"2022","unstructured":"Yokoyama S, Nakagawa C, Hosomi K (2022) Treatment strategy of oxaliplatin-induced peripheral neuropathy: a retrospective, nationwide study. Support Care Cancer 30:1765\u20131773. https:\/\/doi.org\/10.1007\/s00520-021-06585-z","journal-title":"Support Care Cancer"},{"key":"7676_CR29","unstructured":"Pregabalin drug package insert: https:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuDetail\/ResultDataSetPDF\/671450_1190017F1029_3_01. Accessed 6 Feb 2022"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-023-07676-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-023-07676-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-023-07676-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,15]],"date-time":"2023-04-15T08:07:10Z","timestamp":1681546030000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-023-07676-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,13]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["7676"],"URL":"https:\/\/doi.org\/10.1007\/s00520-023-07676-9","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,13]]},"assertion":[{"value":"11 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Institutional Review Board of the Iwate Medical University (IRB approval number: MH2021-009) and was performed in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained in the form of opt-out on the website.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no relevant financial or nonfinancial interests to disclose.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"208"}}